Licensing
In a
first conclusion of
several confidentially negotiated licenses,
Genomic Nanosystems, LLC (GNS) has granted an
exclusive license to Sequenom, Inc.
(Nasdaq: SQNM) for the right to use
a field of
Digital PCR IP for noninvasive prenatal research and diagnostics on a
technology, platform and sample independent basis, and has granted the
exclusive right to use digital PCR in conjunction with mass
spectrometry for any diagnostic or research purpose, excluding second
generation genetic sequencing. Financial terms were not disclosed.
As
explained by Elaine Lanza, Ph.D., Genomic Nanosystems Managing
Partner, “This license is essential in enabling Sequenom to use digital
PCR with their extensive IP in the fields of prenatal testing and
genetic analysis by mass spectrometry. GNS owns the central, core
rights to digital PCR methods, and using this IP will provide Sequenom
with a strong position in developing their genetic analysis and
SEQureDX™ diagnostics businesses.”
SEQureDX™ is a trademark of Sequenom, Inc.
DigitalPCR, cPCR, dPCR, dePCR, d-TAQ, NanoArray and PicoArray
are trademarks of Genomic Nanosystems, LLC, a subsidiary of the Cytonix
Corporation.
Copyright 1995 -- 2008. All rights reserved,
Genomic
Nanosystems, LLC.
|
|